Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 2/20 | 0.63 |
| ▸ | ALPI | P09923 | 1/20 | 0.63 |
| ▸ | PKM | P14618 | 1/20 | 0.63 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.63 |
| ▸ | XIAP | P98170 | 1/20 | 0.63 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.59 |
| ▸ | CTSC | P53634 | 2/20 | 0.58 |
| ▸ | LTA4H | P09960 | 1/20 | 0.56 |
| ▸ | ANPEP | P15144 | 1/20 | 0.51 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.51 |
| ▸ | DNPEP | Q9ULA0 | 1/20 | 0.51 |
| ▸ | BACE1 | P56817 | 2/20 | 0.50 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.50 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.50 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.50 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.50 |
| ▸ | MMP2 | P08253 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7648961 | 1.00 | SLC7A5 (0.63) | SLC7A5ALPIPKMPTGS1XIAP | |
| SCHEMBL583592 | 1.00 | SLC7A5 (0.63) | SLC7A5ALPIPKMPTGS1XIAP | |
| Hydrochloric Acid SCHEMBL1262434 | 0.98 | SLC7A5 (0.61) | SLC7A5ALPIPKMPTGS1XIAP | |
| Hydrochloric Acid SCHEMBL6164795 | 0.98 | SLC7A5 (0.61) | SLC7A5ALPIPKMPTGS1XIAP | |
| Hydrochloric Acid SCHEMBL6164804 | 0.98 | SLC7A5 (0.61) | SLC7A5ALPIPKMPTGS1XIAP | |
| Trifluoroacetic Acid SCHEMBL7268667 | 0.92 | SLC7A5 (0.54) | SLC7A5ALPIPKMPTGS1XIAP | |
| Trifluoroacetic Acid SCHEMBL6967778 | 0.92 | SLC7A5 (0.54) | SLC7A5ALPIPKMPTGS1XIAP | |
| SCHEMBL3704073 | 0.90 | CTSC (0.54) | SLC7A5ALPIPKMPTGS1XIAP | |
| SCHEMBL3704071 | 0.90 | CTSC (0.54) | SLC7A5ALPIPKMPTGS1XIAP | |
| SCHEMBL20669159 | 0.87 | MMP1 (0.61) | CTSCMMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 97 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010049405-A1 | METHOD FOR IMPROVING PLANT HEALTH | BASF SE (DE) | 2010-05-06 | — | — | WO | claimed |
| US-6486193-B2 | ANTIARTHRITIC AGENTS; ANTIINFLAMMATORY AGENTS | AVENTIS PHARMACEUTICALS INC. | 2002-11-26 | — | — | US | claimed |
| US-20020037859-A1 | 3-substituted pyrrolidines useful as inhibitors of matrix metalloproteinases | AVENTISUB INC. | 2002-03-28 | — | — | US | claimed |
| US-5290794-A | Storage stable compositions | WARNER LAMBERT CO. (US) | 1994-03-01 | — | — | US | claimed |
| CN-120004785-A | Compounds and compositions for the treatment of diseases associated with STING activity | 诺华制药股份有限公司 | 2025-05-16 | — | — | CN | disclosed |
| CN-112823036-B | Compounds and compositions for the treatment of diseases associated with STING activity | 艾福姆德尤股份有限公司 | 2024-11-08 | — | — | CN | disclosed |
| US-20240083895-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2024-03-14 | — | — | US | disclosed |
| CN-117561058-A | CDK2 inhibitors and methods of use thereof | 塞迪拉治疗股份有限公司 | 2024-02-13 | — | — | CN | disclosed |
| US-11618749-B2 | Compounds and compositions for treating conditions associated with STING activity | IFM DUE, INC. (US) | 2023-04-04 | — | — | US | disclosed |
| EP-3707140-B1 | PURINE BASED COMPOUNDS AS TOLL-LIKE RECEPTOR 9 ANTAGONISTS | COUNCIL SCIENT IND RES (IN) | 2021-10-13 | — | — | EP | disclosed |
| CN-112823036-A | Compounds and compositions for treating diseases associated with STING activity | 艾福姆德尤股份有限公司 | 2021-05-18 | — | — | CN | disclosed |
| EP-3817820-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | IFM Due, Inc. (US) | 2021-05-12 | — | — | EP | disclosed |
| WO-1992013831-A1 | HYDROXAMIC ACID DERIVATIVES, PROCESS FOR THEIR PREPARATION AND USE THEREOF | BRITISH BIO-TECHNOLOGY LIMITED (GB) | 1992-08-20 | — | — | WO | disclosed |
| EP-0495013-A1 | HEXAPEPTIDES WITH SULPHATE ESTER GROUPS. | FISONS CORP (US) | 1992-07-22 | — | — | EP | disclosed |
| EP-0446267-A1 | HYDROXAMIC ACID BASED COLLAGENASE INHIBITORS. | BRITISH BIO TECHNOLOGY (GB) | 1991-09-18 | — | — | EP | disclosed |
| WO-1991008225-A1 | HEXAPEPTIDES WITH SULPHATE ESTER GROUPS | FISONS CORPORATION (US) | 1991-06-13 | — | — | WO | disclosed |
| EP-0376012-A2 | Renin inhibitors | AMERICAN CYANAMID COMPANY (US) | 1990-07-04 | — | — | EP | disclosed |
| EP-0376040-A2 | N-phosphinyl di-and tripeptides as renin inhibitors | AMERICAN CYANAMID COMPANY (US) | 1990-07-04 | — | — | EP | disclosed |
| WO-1990005719-A1 | HYDROXAMIC ACID BASED COLLAGENASE INHIBITORS | BRITISH BIO-TECHNOLOGY LIMITED (GB) | 1990-05-31 | — | — | WO | disclosed |
| EP-0224151-A2 | 2-Substituted-[2-substituted-amino]-N-aralkyl-3-[indol-3-yl]propanamides | WARNER-LAMBERT COMPANY (US) | 1987-06-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11618749-B2 | Compounds and compositions for treating conditions associated with STING activity | STING1, IRF3, CGAS | SLC7A5 3240/4885ALPI 1701/4885PKM 3471/4885 |
| US-20240083895-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, CGAS, IRF3 | SLC7A5 3202/4885ALPI 2124/4885PKM 3505/4885 |
| US-20020037859-A1 | 3-substituted pyrrolidines useful as inhibitors of matrix metalloproteinases | MMP3, MMP1, MMP9 | SLC7A5 2741/4885ALPI 289/4885PKM 1146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.